Passage Bio

Jill Quigley, Chief Operating Officer

Oct. 12 | 2:45pm | AVROBIO Ballroom

Philadelphia, PA

(NASDAQ: PASG)

In-person Presentation

At Passage Bio, we are on a mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities we serve. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. This provides our team with enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing, and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies into clinical testing. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies.

www.passagebio.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions